These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 9920255)

  • 1. Should platform companies move toward products?
    Ratner M
    Nat Biotechnol; 1999 Jan; 17(1):16-7. PubMed ID: 9920255
    [No Abstract]   [Full Text] [Related]  

  • 2. Biotechs hold their own in shifting industry.
    Mitchell P
    Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
    [No Abstract]   [Full Text] [Related]  

  • 3. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 4. DPI delivers biotechnology superstore. Discovery Partners International.
    Glaser V
    Nat Biotechnol; 1998 Dec; 16(13):1302. PubMed ID: 9853596
    [No Abstract]   [Full Text] [Related]  

  • 5. Financial Times Global Pharmaceutical & Biotechnology Conference 2009.
    Scattereggia J
    IDrugs; 2010 Jan; 13(1):26-9. PubMed ID: 20024844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UK industry consolidation is slow despite big merger.
    Mitchell P
    Nat Biotechnol; 2003 Mar; 21(3):215. PubMed ID: 12610553
    [No Abstract]   [Full Text] [Related]  

  • 7. Antisoma-Roche deal--a new kind of buyout?
    Mitchell P
    Nat Biotechnol; 2003 Jan; 21(1):3. PubMed ID: 12511894
    [No Abstract]   [Full Text] [Related]  

  • 8. Advice for partnering with pharma.
    Howard K
    Nat Biotechnol; 2004 Nov; 22(11):1477-9. PubMed ID: 15586421
    [No Abstract]   [Full Text] [Related]  

  • 9. Hyseq-Variagenics merger signals end of the line.
    Hodgson J
    Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
    [No Abstract]   [Full Text] [Related]  

  • 10. Private company profiles.
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE23-8. PubMed ID: 12874973
    [No Abstract]   [Full Text] [Related]  

  • 11. Can a platform of platform companies open up more opportunities?
    Mullard A
    Nat Rev Drug Discov; 2021 Aug; 20(8):580-581. PubMed ID: 34262143
    [No Abstract]   [Full Text] [Related]  

  • 12. Maturing biotechs turn to pharma's markets.
    Ratner M
    Nat Biotechnol; 2005 Mar; 23(3):269. PubMed ID: 15765067
    [No Abstract]   [Full Text] [Related]  

  • 13. Cheap at any price?
    Ledford H
    Nature; 2007 May; 447(7141):131. PubMed ID: 17495898
    [No Abstract]   [Full Text] [Related]  

  • 14. Value creation and sharing among universities, biotechnology and pharma.
    Edwards MG; Murray F; Yu R
    Nat Biotechnol; 2003 Jun; 21(6):618-24. PubMed ID: 12776145
    [No Abstract]   [Full Text] [Related]  

  • 15. Prescription for an ailing pharmaceutical industry.
    Demain AL
    Nat Biotechnol; 2002 Apr; 20(4):331. PubMed ID: 11923826
    [No Abstract]   [Full Text] [Related]  

  • 16. AchemAsia 2007 announcement: China's biotechnology industry on the upswing.
    Biotechnol J; 2007 Mar; 2(3):288-90. PubMed ID: 17354215
    [No Abstract]   [Full Text] [Related]  

  • 17. Biotech's new colossus. Move over, Big Pharma. Amgen boasts better growth.
    Stipp D
    Fortune; 2002 Apr; 145(8):144-6, 148, 150. PubMed ID: 11961884
    [No Abstract]   [Full Text] [Related]  

  • 18. Study critiques corporate control of trials.
    Niiler E
    Nat Biotechnol; 2002 Dec; 20(12):1180. PubMed ID: 12454659
    [No Abstract]   [Full Text] [Related]  

  • 19. Millennium and Aventis in unique pact.
    Fletcher L
    Nat Biotechnol; 2000 Aug; 18(8):817. PubMed ID: 10932140
    [No Abstract]   [Full Text] [Related]  

  • 20. Biomanufacturing, from bust to boom...to bubble?
    Thiel KA
    Nat Biotechnol; 2004 Nov; 22(11):1365-72. PubMed ID: 15529157
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.